17 October 2024
Physiomics plc
("Physiomics" or the "Company")
Notice of AGM
Physiomics plc (AIM: PYC), a leading
mathematical modelling and data science company supporting the
development of new therapeutics and personalised medicine
solutions, is pleased to provide notice of the Company's Annual
General Meeting ("AGM").
The AGM will be held at 10.30 a.m. on 19
November 2024 at the Company's registered office, Bee House, 140
Eastern Avenue, Milton Park, Oxfordshire, OX14 4SB.
Shareholders will shortly be sent either
printed copies of the Notice of AGM and accompanying materials or a
letter notifying them that they are available on the Company's
website, depending on the preferences they have expressed to the
Company's registrar.
A copy of the Notice of AGM, containing further
details of the resolutions to be proposed at the meeting, as well
as a copy of the Company's Annual Report and Accounts, will be made
available today on the Company's website at www.physiomics.co.uk/investors/corporate-documents/.
Enquiries:
Physiomics
plc
Dr Peter Sargent, CEO
+44 (0)1235 841575
Hybridan LLP
(Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson
Limited (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to
Editor
About Physiomics
Physiomics plc combines expertise
across Modelling & Simulation, Biostatistics, Data Science and
Bioinformatics, together with deep biology expertise, to help
biotech and pharma companies streamline their drug development
journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and
optimise research design across discovery, pre-clinical and
clinical studies. Through use of cutting-edge computational tools,
bespoke models and our proprietary Virtual Tumour technology, the
Physiomics team has informed the development of over 100 commercial
projects, with over 125 targets and drugs modelled. Clients include
Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.
